You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 9,339,510


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,339,510
Title:Azepane derivatives and methods of treating hepatitis B infections
Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
Inventor(s): Hartman; George D. (Landsdale, PA), Kuduk; Scott (Harleysville, PA)
Assignee: NOVIRA THERAPEUTICS, INC. (Doylestown, PA)
Application Number:14/856,761
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of the Claims and Patent Landscape for United States Patent 9,339,510

Introduction

Understanding the intricacies of a patent, particularly one like United States Patent 9,339,510, involves a deep dive into its claims, the patent landscape, and the legal and procedural frameworks that govern it. This analysis will cover the key aspects of patent law, the process of patentability, and the specific context of the patent in question.

Patent 9,339,510: Overview

To begin, it is essential to identify the subject matter of the patent. However, since the specific details of Patent 9,339,510 are not provided, we will use general principles to analyze its potential claims and the broader patent landscape.

Patentability Analysis

Novelty

A patent must meet the novelty requirement, meaning the claimed invention must be new and not previously disclosed in the prior art. This involves a thorough prior art search to ensure that every element of the claimed invention is not already disclosed in existing publications, public use, or sales before the effective filing date of the patent application[5].

Nonobviousness

In addition to novelty, the invention must also be nonobvious. This means that the invention must not be an obvious variation of existing technology to a person of ordinary skill in the relevant field. The analysis involves determining whether the claimed invention would have been obvious at the time of the invention, considering the prior art and any secondary considerations such as commercial success or long-felt but unsolved needs[5].

Utility and Enablement

The patent application must also demonstrate utility, meaning the invention must have a practical application and be capable of being used for its intended purpose. Furthermore, the application must meet the enablement requirement, which means that the specification must provide sufficient detail to enable a person of ordinary skill in the field to make and use the invention[4].

The Patent Process

Application and Examination

The patent process begins with the submission of a patent application to the United States Patent and Trademark Office (USPTO). The application is then evaluated by a patent examiner who reviews the application to ensure it meets the legal requirements of novelty, nonobviousness, utility, and enablement. If the application is rejected, the applicant can amend the application or appeal the examiner’s decision[4].

Appeals and Post-Grant Proceedings

If an applicant is unable to overcome the examiner’s rejections, they can appeal to the Patent Trial and Appeal Board (PTAB). Additionally, post-grant proceedings such as Inter Partes Review (IPR) and Post-Grant Review (PGR) can be initiated to challenge the validity of an issued patent. These proceedings, created under the Leahy-Smith America Invents Act (AIA), provide a faster and more cost-effective way to challenge patent validity compared to federal court litigation[2].

Subject Matter Eligibility

Judicial Exceptions

Patent claims must fall within one of the four statutory categories (processes, machines, manufactures, and compositions of matter) and must not be directed to judicial exceptions such as abstract ideas, laws of nature, or natural phenomena. For AI-related inventions, the USPTO has issued guidance emphasizing the need for claims to integrate judicial exceptions into practical applications, demonstrating specific technical improvements or solutions[3].

Practical Applications

The USPTO guidance highlights the importance of claims that provide a particular solution to a problem or a specific way to achieve a desired outcome. For example, claims to an AI system that improves existing technological processes, such as anomaly detection using an artificial neural network, can be eligible if they demonstrate meaningful limits and practical applications[3].

Trademark and Patent Intersections

While patents protect inventions, trademarks protect brand identities. However, there can be intersections, especially in terms of consumer perception and distinctiveness. For instance, the case of Patent and Trademark Office v. Booking.com B.V. emphasizes that consumer perception is crucial in determining the registrability of a mark. This principle can be analogous in understanding how patent claims are perceived and distinguished in the market[1].

Challenges and Criticisms

Patent Trolls and Litigation

The patent landscape is often criticized for issues related to patent trolls, entities that do not manufacture or sell the patented products but use patents to litigate. The PTAB was created to address these issues by providing a more efficient and cost-effective way to challenge patent validity. However, critics argue that PTAB has made it too easy to challenge patents, creating uncertainty and stifling innovation[2].

Balancing Innovation and Protection

The patent system aims to balance the protection of intellectual property with the promotion of innovation. Overly broad or poor-quality patents can hinder innovation, while robust and well-defined patents can encourage it. The USPTO’s guidance on patent subject matter eligibility, particularly for AI inventions, is a step towards achieving this balance by ensuring that only inventions that provide meaningful technical improvements are patented[3].

Key Takeaways

  • Novelty and Nonobviousness: A patent must be novel and nonobvious to be granted.
  • Utility and Enablement: The invention must have a practical application and be described in sufficient detail.
  • Subject Matter Eligibility: Claims must fall within statutory categories and not be directed to judicial exceptions without practical applications.
  • Post-Grant Proceedings: PTAB provides mechanisms for challenging patent validity post-issuance.
  • Balancing Innovation: The patent system must balance protection with innovation to foster technological advancement.

FAQs

Q: What are the primary requirements for a patent to be granted in the United States?

A: The primary requirements include novelty, nonobviousness, utility, and enablement.

Q: How does the PTAB differ from federal court litigation in challenging patent validity?

A: PTAB proceedings are generally faster, cheaper, and require a lower burden of proof compared to federal court litigation.

Q: What is the significance of the USPTO’s guidance on AI inventions?

A: The guidance provides clarity on how AI-related claims can meet subject matter eligibility requirements by integrating judicial exceptions into practical applications.

Q: Can a descriptive term be registered as a trademark?

A: Yes, but it must achieve secondary meaning or acquired distinctiveness in the minds of the public to be placed on the principal register[1].

Q: What is the role of prior art in patentability analysis?

A: Prior art is used to determine whether the claimed invention is novel and nonobvious by comparing it against existing publications, public use, or sales before the effective filing date of the patent application[5].

Sources

  1. Supreme Court of the United States, Patent And Trademark Office v. Booking.com B.V., 591 U.S. ____ (2020).
  2. Congressional Research Service, The Patent Trial and Appeal Board and Inter Partes Review, Updated May 28, 2024.
  3. Greenberg Traurig LLP, USPTO Issues New Guidance on Patent Subject Matter Eligibility for AI Inventions, July 19, 2024.
  4. PhRMA, IP Explained: How does the U.S. patent process work?, June 24, 2021.
  5. InterSECT Job Simulations, IP: Patentability Analysis, accessed December 20, 2024.

More… ↓

⤷  Subscribe

Details for Patent 9,339,510

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc RECOMBIVAX, RECOMBIVAX HB hepatitis b vaccine (recombinant) Injection 101066 July 23, 1986 9,339,510 2034-01-16
Glaxosmithkline Biologicals ENGERIX-B hepatitis b vaccine (recombinant) Injection 103239 August 28, 1989 9,339,510 2034-01-16
Pharmaand Gmbh PEGASYS peginterferon alfa-2a Injection 103964 October 16, 2002 9,339,510 2034-01-16
Pharmaand Gmbh PEGASYS peginterferon alfa-2a Injection 103964 January 07, 2004 9,339,510 2034-01-16
Pharmaand Gmbh PEGASYS peginterferon alfa-2a Injection 103964 September 29, 2011 9,339,510 2034-01-16
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 June 04, 2004 9,339,510 2034-01-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.